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Human female reproductive aging consists of multiple processes and interacts with other physiological systems
in unique ways. Here we discuss eight recent longitudinal, epidemiologic studies of female reproductive aging that
include endocrine data to highlight their contributions to our understanding of these various aging processes and their
interactions. Specifically, we review data on ovarian and nonovarian reproductive aging processes and reproductive
staging. We consider these data in the context of longitudinal research design and research goals, identify limitations
of the studies but also ways in which existing longitudinal data can further our understanding of aging processes,
and make recommendations for future studies of female reproductive aging.
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Introduction
Understanding the relationship between female re-
productive aging and more general aging processes
is uniquely challenging in modern humans. Few
species and none of our primate relatives have
postreproductive intervals as long, relative to to-
tal lifespan, as those observed in human females.1
Reproductive aging in women appears markedly ac-
celerated against the backdrop of the elongated hu-
man lifespan and the more gradual aging processes
observed in other physiological systems.
Interest in female reproductive aging is not only
evolutionarily based but reflects a desire to address
health concerns that women face at various stages
of reproductive and postreproductive life. Changes
in fertility, menopausal symptoms, and health risks
during and after the menopausal transition are pri-
mary concerns, and research advances continue to
inform decisions about appropriate treatments and
interventions.2 Assessing the interaction among var-
ious aging processes is a necessary part of this re-
search effort. Reproductive aging itself can include
multiple processes that occur at different rates and
whose interactions are not fully understood. Ele-
vated follicle-stimulating hormone (FSH), for ex-
ample, may be a function of final depletion of ovar-
ian follicles (and associated steroid hormones) at
midlife, which in turn releases gonadotropins from
negative feedback, but also could be the result of
gradual changes in hypothalamic-pituitary sensitiv-
ity to this negative feedback.1,3–5 Also, it is not always
clear whether a particular health risk or outcome is
the result of reproductive changes, more generalized
age-related processes, or both.4
Addressing these research challenges requires a
broad approach. Epidemiologic studies represent an
important component of the research effort because
they inform us about female reproductive aging
in population-based samples. The first large-scale
studies of female reproductive function, in the mid-
20th century, were epidemiologic in design and fo-
cused on describing the “normal” menstrual cycle
changes with age.6,7 With the development of mod-
ern assay methodologies that could be implemented
in populations, researchers established normative
hormone profiles in the menstrual cycle8,9 as part
of a larger effort to understand the proximate repro-
ductive functions of the hypothalamic-pituitary-
ovarian axis. Concurrently, clinical researchers were
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identifying conditions in which “normal” reproduc-
tive function was in some way compromised, in an
effort to understand and treat infertility.10 And ob-
servations of postmenopausal estrogen loss, associ-
ated health risks (e.g., osteoporosis, cardiovascular
risk), and the potential for hormone replacement
therapy to reduce those risks, became a primary fo-
cus area.1,5
These research efforts laid the groundwork for
more recent longitudinal, epidemiologic studies to
characterize female reproductive aging in commu-
nity samples and to reflect the sources of variation
that may be contributed by race/ethnicity, body size,
or behavioral practices. The studies vary in terms
of research goals and therefore in hormonal, men-
strual, and covariate measures, but the projects to-
gether provide an important body of data. In this
chapter, we focus on eight of these studies, specifi-
cally those that have assessed reproductive hormone
changes with age. Several of these studies have been
reviewed elsewhere as parts of broader discussions
of female reproductive aging, including the relation-
ship and interactions between reproductive aging
and more generalized aging processes.1,4,11,12 Here,
we consider the findings of these studies in terms of
ovarian and nonovarian aging processes, research
goals and epidemiologic study design, and sugges-
tions for future research efforts.
Study summaries
The following is a summary of longitudinal, epi-
demiologic studies of reproductive aging that have
been established within the last 25 years, and have
endocrine measures, reasonable retention, and suf-
ficient duration of follow-up to describe important
physiological processes. In most, but not all cases,
the age range of participants reflects a focus on peri-
menopause. Many of the studies are based on cross-
sectional studies in order to establish some degree
of generalization to community samples.
There is a notable contrast across studies in hor-
mone sampling, which reflects differences in overall
research goals. Those studies that aim to develop
a broad, global understanding of the menopausal
transition and collect data on a wide range of vari-
ables, including social, behavioral, and physiolog-
ical factors, tend to have annual or monthly hor-
mone measures that can be analyzed in conjunction
with many other variables over a number of years.
Annual hormone measures are taken in the early
to middle follicular phase, which is easily identifi-
able relative to the menstrual period. Such measures
can not, however, provide information about ovu-
latory status or within-cycle hormone patterns, and
may or may not be comparable to other studies that
sampled on slightly different days of the follicular
phase. Those studies that focus more on the physio-
logical, mechanistic underpinnings of reproductive
aging generally take more frequent (e.g., weekly or
daily) samples which allow for analyses of changes in
within- and across-cycle hormone dynamics (e.g.,
peak progesterone, luteinizing hormone [LH], or
FSH occurring outside the follicular phase) and
ovulatory status. The drawbacks of an intensive col-
lection routine are financial and time constraints,
participant burden, and (usually) lower participant
numbers compared with annual-measure studies.
With these factors in mind, the studies are de-
scribed here in the time order of their development,
and key features are compared in Figure 1.
Massachusetts Women’s Health Study
(MWHS)—longitudinal component:
1986–1991
The goal of the MWHS was to describe how women
respond to the menopausal transition, and to de-
termine how social, behavioral, and physiological
factors affect women’s experiences of the transi-
tion.13 Initially, white women (n = 8050) from the
greater Boston area who were not postmenopausal
(<11 months amenorrhea) were followed from
1981 to 1986 (ages 45–55 at baseline). Multiple
questionnaires covering menstrual, health, lifestyle,
and sociodemographic characteristics were admin-
istered.13 A second component of the study (MWHS
II; 1986–1991; n = 427 from original cohort) in-
cluded annual collection of biomarker data.14,15
These participants (ages 50–60 years) had an in-
tact uterus, at least one ovary, and no more than
11 months of amenorrhea.5 Annual blood samples
(from day 5 to 7 of menstrual cycle) were assayed
for estradiol (E2) and FSH. Data were excluded if
women used exogenous hormones or were missing
predictor or outcome measures.
Specific topics addressed in the MWHS included
menopausal symptoms, sexual function, depres-
sion, healthcare utilization, weight, cardiovascu-
lar health, women’s attitudes about menopause,
and reproductive hormone patterns.13 The study
was particularly important in demonstrating for
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Figure 1. Longitudinal, epidemiologic studies of female reproductive aging that include substantial endocrine data. Studies
are in order from least to most recent start date (top to bottom). Box width depicts the baseline age range of participants for
each study. Number of years listed on line to the right of each box is the maximum number of years during which endocrine
data were/are collected; arrow indicates that a study is ongoing. Information to the right includes sampling strategy, hormones
measured, allowable menopausal stages at baseline, and ethnicity. All annual or monthly samples were taken during the early
follicular phase of the menstrual cycle. Across all studies, women were excluded if they did not have at least one ovary, were pregnant
or breastfeeding, or were taking exogenous hormones or other medications known to affect reproductive hormone values. MWHS,
Massachusetts Women’s Health Study; MWMHP, Melbourne Women’s Midlife Health Project; SMWHS, Seattle Midlife Women’s
Health Study; MBHMS, Michigan Bone Health and Metabolism Study; SWAN, Study of Women’s Health Across the Nation; POAS,
Penn Ovarian Aging Study; BIMORA, Biodemographic Models of Reproductive Aging project; FREEDOM, Fertility Recognition
Enabling Early Detection of Menopause study. Hormones: C, cortisol; AMH, anti-Müllerian hormone; E2, estradiol; E1c/E1g,
estrogen conjugates; FSH, follicle-stimulating hormone; LH, luteinizing hormone; PdG, pregnanediol glucuronide; T, testosterone;
SHBG, sex hormone-binding globulin; DHEAS, dehydroepiandrosterone sulfate.
the first time and in a community-based sam-
ple the generally positive attitudes of women in
the menopausal transition, and that some nega-
tive experiences at midlife may not be menopause-
specific but rather age-related psychosocial and
physiological changes.13 The annual biomarkers
allowed for additional longitudinal analyses of
associations among biological reproductive hor-
mones and other biological and psychosocial fac-
tors, such as depression, weight, and menstrual cycle
characteristics.14,16
Melbourne Women’s Midlife Health Project
(MWMHP)—longitudinal component:
1991–2004
The MWMHP was similar to the MWHS in ad-
dressing a variety of physiological, social, and be-
havioral factors associated with the menopausal
transition. This study also focused more specif-
ically on hormonal changes of the transition.11
A cross-sectional sample of 2001 Australian-born
white women (45–55 years of age) was the sam-
pling frame for the study’s longitudinal component.
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The longitudinal study included 438 women who
initially had menstruated within 3 months of ex-
amination and were without exogenous hormone
use. Women participated in annual health, men-
strual, and hormone data collection over a subse-
quent 13-year period.17 Annual blood samples were
collected (from days 4 to 8 of menstrual cycle or after
3 months of amenorrhea) and assayed for E2, FSH,
inhibin A, inhibin B, immunoreactive total inhibin,
testosterone (T), and sex hormone-binding globulin
(SHBG).17–19
Factors addressed by the MWMHP included
mood, sexual function, cholesterol levels, bone den-
sity, weight, hormone therapy, well-being and qual-
ity of life, menopausal symptoms, cardiovascular
health, diet, and cognition.17 The MWMHP was
one of the first studies to show long-term changes
in a number of reproductive hormones and in men-
strual cycle characteristics, relative to the timing of
the final menstrual period (FMP). It also identified
associations between reproductive hormones and
variables, such as menopausal symptoms, menstrual
cycle characteristics, sexual function, and lipids and
blood pressure.11
Seattle Midlife Women’s Health Study
(SMWHS)—longitudinal component:
1996–2005
The SMWHS, initiated in 1990, also addressed a
wide range of menstrual and health factors poten-
tially associated with the menopausal transition.20 A
multi-ethnic community sample (recruited by tele-
phone) of women (n = 367, ages 35–55 years, me-
dian age 41 at baseline, 20% nonwhite [black, Asian,
Native American]) was characterized with annual
health and more intensive menstrual data by diary.
Commencing in 1996, a subsample of women (n =
170) was selected for a more detailed evaluation of
hormonal changes.21 Women were excluded if they
had not menstruated in the past 12 months, had
both ovaries removed, or were unable to speak or
understand English. Eligible women provided a sin-
gle “day 6” urine specimen for eight to 12 menstrual
cycles per year from 1996 to 2000 and quarterly
from 2001 to 2005.21 Urine samples were assayed
for estrone glucuronide (E1g), follicle-stimulating
hormone (uFSH), testosterone (uT), and cortisol
(uC).
Specific topics addressed by the SMWHS in-
cluded women’s perceptions and expectations
of menopause, mood and depression, memory,
menopausal symptoms, hormone therapy, well-
being, stress, and menopausal stages, for example,
Refs. 22 and 23. Endocrine data have been assessed
in relation to factors, such as menopausal symptoms
and stages, and genetic polymorphisms in the estro-
gen pathway.21,24 The wider age range and multi-
ethnic nature of the participants in this study was
also different from the earlier studies.
Michigan Bone Health and Metabolism Study
(MBHMS)—longitudinal study: 1992–present
The MBHMS is a population-based longitudinal
study with a primary focus on the relationships
among reproductive hormones, musculoskeletal
and metabolic diseases, and health risks.25,26 A total
of 664 white women (24–44 years at baseline) were
recruited using two sampling frames to generate the
population census from which 81% were success-
fully recruited. Participants have provided annual
blood and urine specimens (days 2–7 of menstrual
cycle, or on the anniversary of study enrollment for
those participants with increasingly irregular cycles)
and menstrual and health data. Among a range of
other analytes, serum has been assayed for E2, T,
SHBG, FSH, anti-Müllerian hormone (AMH), and
inhibin B.25–27
The MBHMS has investigated potential relation-
ships between reproductive hormones and factors,
such as bone mineral density, osteoarthritis, physical
activity, body composition, and metabolic biomark-
ers, for example, Refs. 27–29, and has also modeled
changes in estrogen and FSH relative to the tim-
ing of menopause.25,26 The study is also notable in
having the youngest age range at baseline of all the
studies discussed here, allowing it to more fully ad-
dress the transition though reproductive aging into
the postmenopause.
Study of Women’s Health Across the Nation
(SWAN)—longitudinal component:
1996–present
SWAN is investigating social and biological factors
associated with aging and the menopausal transi-
tion. It is one of the most comprehensive of the
studies described here, in the sense that it attempts
to measure a large number of variables and poten-
tial confounding factors, and to collect both annual
and daily endocrine data.30 The initial longitudi-
nal study was based on a cross-sectional survey of a
multi-ethnic, community-based sample of women
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(n = 16,063; ages 40–55) from seven study sites.31
From this survey, a subset of 3-302 women (ages
42–52 at baseline) was selected. To be enrolled in
the study, women were still menstruating, had an
intact uterus and at least one ovary, and could not
be pregnant or taking exogenous hormones.32 En-
rollees self-identified as African-American (25%),
Caucasian (50%), Chinese (8%), Hispanic (8%),
and Japanese (9%). There have been assays of
early follicular phase FSH, E2, T, SHBG, and dehy-
droepiandrosterone sulfate (DHEAS) in the annual
serum collections.33 Interview and diary data in-
cluded information about each woman’s menstrual
cycle.
A multi-ethnic subset of 848 women are tak-
ing part in the longitudinal Daily Hormone Study
(DHS) in which women collect daily first-morning
urine samples during one menstrual cycle (or an in-
terval of 50 days), annually; these urine specimens
are analyzed for estrone conjugates (E1c), pregnane-
diol glucuronide (PdG), uFSH, and uLH.32
The topics investigated in SWAN are extensive
and include analyses of health, psychosocial, and
biomarker data.34 The endocrine data for SWAN
are unique because they include, for an unprece-
dented number of women in a multi-ethnic sam-
ple, both annual and daily (for one menstrual cy-
cle per year) data. The annual data, for example,
have contributed to our understanding of long-term
changes in hormones with reproductive age.33 The
daily data allow for analyses of potential associa-
tions among health and psychosocial factors (e.g.,
hypothalamic-pituitary function, sleep, bone min-
eral density, cardiovascular risk) and within-cycle
hormone patterns and ovulatory status, for exam-
ple, Refs. 30, 32, 33, and 35–40.
The Penn Ovarian Aging Study
(POAS)—longitudinal component:
1996–present
The POAS was designed to “identify hormonal, clin-
ical, behavioral, and demographic factors associ-
ated with ovarian aging” (p. 544).41 Participants
were 436 randomly selected black and white women
from Philadelphia County (35–47 years at baseline)
who had had a regular menstrual cycle (22–35 days
long) within the 3 months prior to enrollment. Sin-
gle day hormone data (day 1–6 of menstrual cy-
cle) were collected four times between 1996 and
2004, with approximately 2 years between collec-
tion times.42 Women also kept a record of menstrual
cycles.42 Women had an intact uterus and at least
one ovary and were absent health states that might
affect ovarian or hormonal function.41 Blood sam-
ples were assayed for E2, FSH, LH, inhibin B, and
DHEAS.43
The POAS focuses on the relationship between
endocrine changes related to ovarian aging (see fur-
ther) and a variety of potentially associated factors,
including menopausal symptoms, sleep, depression,
weight gain, physical activity, menstrual bleeding
patterns, and sexual function, for example, Refs.
43–46.
The Biodemographic Models of Reproductive
Aging (BIMORA) project–longitudinal study:
1998–2002
The BIMORA project was developed to assess the
hormonal and menstrual changes occurring with
reproductive aging and to understand how these
changes are related to the process of follicular de-
pletion, whereby the ovary is ultimately depleted of
ova and their associated steroid hormones. Enrollees
were 156 white women (ages 25–58; mean 47.6
years at baseline) drawn from participants in the
TREMIN Research Program on Women’s Health.47
Enrollees collected daily urine samples for 6 months
(January–July) for 5 consecutive years (1998–2002)
while continuing to provide menstrual diary data.
At baseline, women had to have at least one ovary,
and could not be pregnant, breastfeeding, or using
exogenous hormones. The urine specimens were as-
sayed for E1g, PdG, uFSH, and uLH.47,48
Similar to SMWHS, MBHMS, and POAS, the par-
ticipant age range of the BIMORA study was wide,
with a low minimum age at baseline, to capture
any endocrine changes that might occur earlier in
adult reproductive life. The BIMORA project was
the first to collect daily data for multiple consec-
utive menstrual cycles from each participant. This
type of data allowed for the modeling of individual
6-month trajectories of steroid and gonadotropin
hormones over as many as 5 consecutive years.47,48
It has also allowed for analyses of within-cycle hor-
mone dynamics, including frequency of anovulation
with age, and changes in progesterone, estrogen,
and unopposed estrogen with age or menopausal
stage.49,50
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The Fertility Recognition Enabling Early
Detection of Menopause (FREEDOM)
study—longitudinal component: 1998–2000
The FREEDOM study is similar to the BIMORA
study in that it was designed to understand changes
in reproductive hormones and menstrual cycle dy-
namics at the daily level.51–54 The sample was 112
white British women (ages 30–58; median 44 years at
baseline) volunteers. They collected daily urine sam-
ples and menstrual bleeding data for 6–18 months,
consecutively. Urine specimens were assayed for
E1g, PdG, uFSH, and uLH. Women were excluded
if they were pregnant or breastfeeding, using exoge-
nous hormones, or had pituitary disorders.51
The FREEDOM study has demonstrated im-
portant relationships among the reproductive hor-
mones and cycle characteristics within and across
consecutive menstrual cycles, including the relation-
ship between FSH, follicular phase length, and age51
and the lengthening of the follicular phase associ-
ated with estrogen that remains low for a portion of
the follicular phase.53
Hormonal changes with reproductive age
Epidemiologic studies provide an opportunity to
evaluate hormonal changes at both the individual
and population levels, and the eight studies just de-
scribed have variously extended our understanding
of some of the key hormonal changes that occur
during female reproductive aging.
Declining inhibin B and AMH (products of the
ovarian follicles) are emerging as some of the earli-
est indicators of approaching perimenopause. These
declines, which occur during late premenopause
when menstrual cycles are still regular, are thought
to reflect the dwindling pool of ovarian follicles.
Furthermore, concurrently increasing FSH may re-
flect a decrease in negative feedback control by
these ovarian hormones.11,12,33 The MWMHP was
one of the first studies to describe this late pre-
menopausal decline in inhibin B alongside a slight
rise in FSH, in a population sample.11 Findings from
the POAS44,55,56 and the MBHMS57 were similar and
the latter showed that AMH declines to values below
detection 5 years before the FMP.57
When variation in menstrual cycle length starts to
occur during early perimenopause, a combination
of elevated FSH and maintained or elevated estrogen
has been observed, which may indicate that remain-
ing ovarian follicles are being hyperstimulated by el-
evated FSH.58 In the MWHS, cohort E2 averages did
not change significantly across three annual follow-
up measures, even though the percentage of pre-
menopausal women decreased through time.14 The
SMWHS and the FREEDOM study found that E1g
remained stable during early perimenopause.21,51
The MWMHP found that FSH increased up to and
beyond the FMP and then leveled off, while E2 was
sustained until 2 years before the FMP.11,18 In the
MBHMS, population-average E2 remained stable
from −10 to −2 years before the FMP.26 Elevated
estrogen has been observed in the BIMORA study
and in earlier work by some of the SWAN inves-
tigators50,59 in which daily hormone data could be
analyzed for complete menstrual cycles. Variability
in estrogen within and across cycles, the age ranges
of participants, and differences in sampling schemes
may partly explain the different results across
studies.
Rapid declines in estrogen occur during late per-
imenopause (when variable menstrual cycle length
becomes more pronounced), largely in the 2 years
before the FMP.11,26 This decline is thought to re-
flect the imminent depletion of estrogen-producing
ovarian follicles. Several of the epidemiologic stud-
ies have identified this estrogen decline at the pop-
ulation or individual levels.11,21,26,33,44,47 Annual
measures have the advantage of being able to char-
acterize the drop in estrogen relative to the FMP, and
can estimate the rates of the decline. Daily measures
are informative in showing trajectories of declining
estrogen for individual women.47,50
Some menopausal changes may extend beyond
the process of follicular depletion. Increasing FSH
may be in part the result of an aging hypothalamic-
pituitary axis60 in which gonadotropin pulsatility
changes and the responsiveness to ovarian steroids
decreases.3,12 Also, indirect evidence suggests the
possibility of reduced LH sensitivity to estrogen:
although cycle-average estrogen levels are lower
for anovulatory cycles,40,49 some anovulatory cy-
cles have follicular phase estrogen levels similar to
ovulatory cycles40 yet do not elicit an LH surge.
Other age-related changes to the oocytes and
ovarian tissues may also be affecting cell func-
tion, including chromosomal mutations, decreas-
ing telomere length, and accumulating metabolic
debris.61,62 It remains understudied as to how envi-
ronmental factors affect declining oocyte quality or
ovarian tissues, or how these changes interact with
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the process of follicular depletion. While direct mea-
surements of such changes at the cellular and tissue
levels are challenging in longitudinal epidemiologic
studies, these studies may generate indirect evidence
for relationships among oocyte quality, ovarian tis-
sue function, and follicular depletion. For example,
smoking is known to affect egg and ovary quality63
and has also been shown (Sowers et al.63a) to be as-
sociated with earlier menopause and faster rates of
AMH decline.
Defining reproductive stages
At late reproductive ages, generally menstrual cy-
cles become shorter, and then cycle length vari-
ability increases during perimenopause.6 On the
basis of such changes, many of the epidemiologic
studies have used series of menstrual bleed data
(in some cases complemented by hormone values)
to establish population-based reproductive staging
paradigms.20,25,26,50,54,64–72 Certain levels of change
from the menstrual cycle “norm” of earlier repro-
ductive ages are defined as marking entry into the
next stage of reproductive aging. In this way, data
can be grouped for women of similar biological
age regardless of their chronological ages. The high
level of variation in aging trajectories and age at
menopause also makes staging systems particularly
valuable for giving women an idea of their proxim-
ity to menopause. It should be noted, however, that
the common staging systems in use today have been
developed in large part from consensus discussions,
not all women go through all stages or expected
sequences of stages, and FMP can not be precisely
predicted by any staging system.
The Stages of Reproductive Aging Workshop
(STRAW) reproductive staging system66 consists of
seven stages. The mid- to late reproductive stages are
indicated by regular cycles and lower FSH, followed
by regular cycles and elevated FSH. In the peri-
menopausal stages, FSH remains elevated and cycles
change from variable length to intermenstrual inter-
vals greater than 60 days. Recent analyses69,70 have
applied the STRAW system to multiple longitudinal
menstrual cycle diary data (MWMHP, TREMIN,
SMWHS, SWAN) in order to test the utility of the
stages for determining entry into early and late per-
imenopause, and for determining time to FMP. The
use of cycle variability >6 days for defining early
perimenopause, and the use of a first >60 day inter-
menstrual interval for entering late perimenopause,
were supported, but additional research is needed
to identify more precise markers of the early
perimenopause.
Multiple hormone values or hormonal patterns
across a menstrual cycle have also been proposed
for refining reproductive stages, since it is clear that
single hormone values (e.g., FSH) do not provide
significantly different information about proximity
to the FMP than menstrual cycle changes.65,69 Miro
et al.54 proposed a five-stage classification based on
FSH and menstrual cycle characteristics that dif-
fers from STRAW by defining an FSH threshold for
each stage and by including in the definitions cycles
with delayed follicular development and anovula-
tion. This method may be difficult to apply in clin-
ical settings where, for example, anovulatory cycles
can not easily be identified. Longitudinal analyses
of annual FSH25 and E226 measures in the MBHMS
study have shown systematic rates of change and
acceleration of change in FSH and E2 that can be
characterized in definable stages in the years around
the FMP. It should be noted that even these multi-
sample methods do not provide precise information
about time to FMP.
Limitations and future research
Researchers are cognizant of several issues that limit
the analyses that can be done with longitudinal data.
First, age ranges of participants in most of the stud-
ies described were in the 40s and early 50s, and
consideration of those early or mid-late reproduc-
tive events that entrain events of the late reproduc-
tive age were thereby excluded from study. Second,
epidemiologic studies may be constrained to incor-
porate exclusion criteria that preclude certain pop-
ulation segments (e.g., ethnicity, hormone therapy
users, early or late entrants into a particular repro-
ductive stage), thus limiting generalizability of re-
sults. Finally, as discussed above, the hormone sam-
pling strategies used in longitudinal studies vary,
from large samples of annual measures to smaller
samples of daily hormone measures, thus limiting
the types of analyses that can be done in each type
of study.
One of the goals in female reproductive aging re-
search continues to be to understand attributes lead-
ing up to and following the FMP. For studies with an-
nual hormone data, additional data can be pursued
using archival specimens, including genetic data,
for additional assays thought to be associated with
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reproductive aging. It is possible that a combina-
tion of hormonal and genetic markers from a single
annual specimen, along with specific covariate and
menstrual cycle data, could improve upon current
reproductive staging efforts. To achieve this, how-
ever, specimens and suitable analytical techniques
must be available.
For studies with daily hormone data, existing data
on full and sequential menstrual cycles could be used
to develop sampling strategies for predicting time to
FMP and to identify subtle relationships among hor-
mone changes across the various parts of the men-
strual cycle. Indeed, a main advantage of existing
daily hormone data is that they allow for analyses of
sampling strategies or hormonal relationships out-
side of the early follicular phase. Because daily data
span the menstrual cycle, however, external mark-
ers, apart from actual menstrual bleeding, would be
required to relate to the timing of the various parts
of their cycle (e.g., initial estrogen rise, ovulation,
luteal phase). The daily hormone studies could also
add genetic and additional hormone assay data from
archival specimens, but these may require additional
analytical work to understand how the urinary ex-
cretion levels are related to cellular and molecular
attributes.
The combination of rich longitudinal data from
the perimenopause and postmenopause could be
invaluable for showing associations between per-
imenopause, health outcomes (e.g., osteoporosis,
cardiovascular disease), and other aging processes.
The heath-related outcomes will need to be com-
mon because the sample sizes of most studies of
longitudinal aging preclude having sufficient health
events to identify, for example, cancers, autoim-
mune disorders for which women are dispropor-
tionately affected, or neurological impairments that
may disproportionately affect women.
Genetic markers are likely to become an increas-
ingly common tool in longitudinal studies. Already,
some longitudinal studies have examined relation-
ships between specific polymorphisms in the es-
trogen pathway and later reproductive and health
outcomes.73 Markers for differences in follicular de-
pletion rate and markers for specific disease states
are likely to grow in number, and it will be impor-
tant for existing studies with specimens to consider
if and how additional genetic markers can inform
their studies. More generally, the use of repositories
for specimens and data sets will become increasingly
important. The longitudinal studies are in various
stages in terms of making their data available to
others; most of those studies for which data are not
yet available to others are still in the active analysis
phase. Others may require additional resources to
engage in broad data sharing.
Existing longitudinal studies can play an impor-
tant role in informing future study designs in human
female reproductive aging, through an appreciation
of both their limitations and their accomplishments.
Expanded age ranges, careful consideration of co-
variates that modify the rate of follicular depletion
or other aging processes, tracking of women over
long periods of time, and plans for specimen and
data storage and sharing should all be considered.
Although there are limits to what any single study
can do, collaborative efforts across multiple study
sites may have potential for identifying key linkages
between reproductive aging and age- and disease-
related health issues. In addition, future studies will
likely be enhanced by ever-improving technologi-
cal innovations in the areas of biological imaging,
hormonal assays, blood sampling methods, genetic
methods, and bioinformatics.
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